Last reviewed · How we verify

Adalat (Nifedipine, BAYA1040) — Competitive Intelligence Brief

Adalat (Nifedipine, BAYA1040) (Adalat (Nifedipine, BAYA1040)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker (dihydropyridine). Area: Cardiovascular.

marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Adalat (Nifedipine, BAYA1040) (Adalat (Nifedipine, BAYA1040)) — Bayer. Nifedipine blocks calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and reduced blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Adalat (Nifedipine, BAYA1040) TARGET Adalat (Nifedipine, BAYA1040) Bayer marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Telmisartan + Amlodipine Telmisartan + Amlodipine Daewon Pharmaceutical Co., Ltd. marketed Angiotensin II receptor blocker + Calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels
Lacidipine & Amlodipine Lacidipine & Amlodipine Korea University Guro Hospital marketed Dihydropyridine calcium channel blocker L-type voltage-gated calcium channel
Calcium Channel Blockers Calcium Channel Blockers Hospital de Clinicas de Porto Alegre marketed Calcium channel blocker L-type voltage-gated calcium channel
Amlodipine 5 or 10 mg(oral) Amlodipine 5 or 10 mg(oral) GlaxoSmithKline marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Amlodipine+Benazepril Amlodipine+Benazepril TSH Biopharm Corporation Limited marketed Calcium channel blocker + ACE inhibitor combination L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Amlodipine/Atorvastatin Amlodipine/Atorvastatin Pfizer's Upjohn has merged with Mylan to form Viatris Inc. marketed Calcium channel blocker / HMG-CoA reductase inhibitor (statin) combination L-type voltage-gated calcium channels / HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker (dihydropyridine) class)

  1. Bayer · 2 drugs in this class
  2. Beijing Tiantan Hospital · 2 drugs in this class
  3. GlaxoSmithKline · 1 drug in this class
  4. Guangzhou First People's Hospital · 1 drug in this class
  5. Organon and Co · 1 drug in this class
  6. Peking University First Hospital · 1 drug in this class
  7. Pfizer Inc. · 1 drug in this class
  8. SK Chemicals Co., Ltd. · 1 drug in this class
  9. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
  10. Shanghai Shyndec Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adalat (Nifedipine, BAYA1040) — Competitive Intelligence Brief. https://druglandscape.com/ci/adalat-nifedipine-baya1040. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: